S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q1 2021

Baker Bros Advisors

Period: Q1 2021 Β· Filed: 2021-05-17
View on SEC EDGAR β†—
AUM
$23.07B
Total portfolio value
Positions
126
Reported securities
Top Holding
SGEN
28.5% $6.56B
QoQ Changes
+8 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2021-05-17) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
SGENSeagen Inc.$6.56B28.46%β€”β€”
28.5%
ONCBeiGene, Ltd.$4.06B17.61%$348.08$297.65-14.5%
17.6%
INCYIncyte Corporation$2.60B11.28%$81.27$116.86+43.8%
11.3%
KODKodiak Sciences Inc.$1.57B6.82%$113.39$38.54-66.0%
6.8%
ACADACADIA Pharmaceuticals Inc.$1.08B4.69%$25.80$25.97+0.7%
4.7%
ALXNAlexion Pharmaceuticals, Inc.$610.6M2.65%β€”β€”
2.6%
NVTAQInvitae Corporation$601.8M2.61%β€”β€”
2.6%
BMRNBioMarin Pharmaceutical Inc.$573.1M2.48%$75.51$58.99-21.9%
2.5%
ASNDAscendis Pharma A/S$456.3M1.98%$128.88$274.50+113.0%
2.0%
PRLDPrelude Therapeutics Incorporated$438.7M1.90%$43.33$4.91-88.7%
1.9%
ABCLAbCellera Biologics Inc.$354.9M1.54%$33.96$8.11-76.1%
1.5%
ARGXargenx SE$308.3M1.34%$275.39$939.68+241.2%
1.3%
IGMSIGM Biosciences, Inc.$242.0M1.05%β€”β€”
1.1%
MRTXMirati Therapeutics, Inc.$241.5M1.05%β€”β€”
1.1%
MDGLMadrigal Pharmaceuticals, Inc.$175.4M0.76%$116.97$528.10+351.5%
0.8%
AMRNXXXXAmarin Corporation plc$164.3M0.71%β€”β€”
0.7%
GBTGlobal Blood Therapeutics, Inc.$131.1M0.57%β€”β€”
0.6%
BCRXBioCryst Pharmaceuticals, Inc.$129.3M0.56%$10.17$9.84-3.2%
0.6%
IMCRImmunocore Holdings plc$107.3M0.47%$42.57$32.50-23.7%
0.5%
PACBPacific Biosciences of California, Inc.$106.7M0.46%$33.31$1.68-95.0%
0.5%
TILInstil Bio, Inc.$97.7M0.42%$501.60$7.73-98.5%
0.4%
TLISTalis Biomedical Corporation$97.3M0.42%β€”β€”
0.4%
HRTXHeron Therapeutics, Inc.$97.2M0.42%$16.21$0.44-97.3%
0.4%
CERSCerus Corporation$82.4M0.36%$6.01$3.16-47.4%
0.4%
ALLKAllakos Inc.$80.7M0.35%β€”β€”
0.3%
DBVTDBV Technologies S.A.$77.9M0.34%$10.66$15.82+48.4%
0.3%
NRIXNurix Therapeutics, Inc.$76.3M0.33%$31.09$23.97-22.9%
0.3%
KYMRKymera Therapeutics, Inc.$76.1M0.33%$38.86$113.51+192.1%
0.3%
RYTMRhythm Pharmaceuticals, Inc.$74.0M0.32%$21.27$114.17+436.8%
0.3%
INSMInsmed Incorporated$73.4M0.32%$34.06$111.60+227.7%
0.3%

Quarter-on-Quarter Activity

Q1 2021 vs. Q4 2020

New Positions (8)

TickerIssuerNotionalSince Filing
IMCRImmunocore Holdings plc$107.3M-23.7%
TILInstil Bio, Inc.$97.7M-98.5%
TLISTalis Biomedical Corporation$97.3M
DSGNDesign Therapeutics, Inc.$43.0M
ACHLAchilles Therapeutics plc$42.9M
OTICOtonomy, Inc.$18.4M
EWTXEdgewise Therapeutics, Inc.$16.3M
Sarepta Therapeutics, Inc.$12.0M

Exited Positions (8)

TickerIssuerNotional
ADPTAdaptive Biotechnologies Corporation$22.4M
GWPHGW Pharmaceuticals plc$13.0M
FPRXFive Prime Therapeutics, Inc.$11.4M
VXRTVaxart, Inc.$8.0M
NTLAIntellia Therapeutics, Inc.$6.1M
GOSSGossamer Bio, Inc.$4.7M
DRNADicerna Pharmaceuticals, Inc.$2.3M
OVIDOvid Therapeutics Inc.$2.2M

Increased (8)

TickerIssuerNotionalShares Ξ”
EVFMEvofem Biosciences, Inc.$3.7M+555.6%
GBTGlobal Blood Therapeutics, Inc.$91.3M+249.6%
NGMNGM Biopharmaceuticals, Inc.$5.3M+173.7%
IMTXImmatics N.V.$25.3M+121.2%
ORTXOrchard Therapeutics plc$3.9M+120.9%
APLSApellis Pharmaceuticals, Inc.$20.6M+86.7%
VSTMXXXXVerastem, Inc.$20.4M+67.8%
TCRRTCR2 Therapeutics Inc.$0.5M+59.1%

Trimmed (8)

TickerIssuerNotionalShares Ξ”
FREQFrequency Therapeutics, Inc.$-29.7M-93.5%
IFRXInflarx N.V.$-3.8M-83.9%
IDRAIdera Pharmaceuticals, Inc.$-14.3M-55.6%
ALXNAlexion Pharmaceuticals, Inc.$-758.2M-54.4%
SGMOSangamo Therapeutics, Inc.$-8.0M-50.0%
AUTLAutolus Therapeutics plc$-4.3M-41.0%
GMDAQGamida Cell Ltd.$-4.6M-33.0%
HRMYHarmony Biosciences Holdings, Inc.$-2.4M-31.3%
← Back to Hedge Funds